A nkylosing spondylitis (AS) is a chronic immunemediated inflammatory disease that predominantly affects the spine and sacroiliac joints. 1 Structural damage in AS is characterized by excessive bone formation, with syndesmophytes as the typical lesion. 2, 3 New bone formation in AS can eventually lead to decreased spinal mobility, which in turn diminishes the patient's ability to perform daily activities and may severely reduce healthrelated quality of life. 4, 5 Therefore, an accurate early diagnosis of AS is of great importance to prevent functional disability and to improve prognosis. 6, 7 Currently, the diagnosis of AS in early stage is mainly based on clinical, radiographic, and biochemical findings, such as inflammatory low back pain, unilateral or bilateral sacroiliitis, HLA-B27 positivity, elevated C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR), which have been documented with limited diagnostic value. [8] [9] [10] Moreover, there is often a delay of 5 to 10 years between symptom onset and diagnosis in most patients with AS. 11, 12 Hence, there is an urgent need to explore novel biomarkers with more high sensitivity and specificity for the diagnosis of AS, especially for early-stage AS.
Recently, the discovery of microRNAs (miRNAs) has paved a new avenue for both the diagnosis and treatment of cancers and other diseases. 13 miRNAs are a novel class of noncoding RNAs that negatively modulate gene expression by translational repression or induction of messenger RNA degradation. 13 Accumulating evidence suggests that miRNAs are present in plasma, serum, saliva, urine, and other body fluids in a remarkably stable form that is protected from endogenous RNase activity. [14] [15] [16] More importantly, circulating miRNAs have been identified as novel noninvasive biomarkers for various diseases such as cancer, 17 cardiovascular disease, 18 sepsis, 19 and liver injury. 20 Of note, recent studies have demonstrated that miRNAs also play an important role in regulating immune response, as well as immune cell development. For instance, the expression profile of circulating miRNAs has the potential to identify systemic rheumatic diseases, including systemic lupus erythematosus (SLE), 21 rheumatoid arthritis (RA), 22 and multiple sclerosis (MS). 23 Therefore, a unique circulating miRNA expression pattern may exist in AS, which may provide reliable biomarkers for AS. However, the global serum miRNAs pattern in AS patients has never been determined. In the current study, we employed high-throughput Solexa (Illumina, San Diego, CA) sequencing scanning followed by a stem-loop quantitative reverse-transcription PCR (qRT-PCR) assay to systematically and extensively evaluate the potential of serum miRNAs as novel noninvasive biomarkers for the diagnosis of AS.
MATERIALS AND METHODS

Subjects and Study Design
The study subjects consisted of 80 sporadic AS patients and 78 age-and sex-matched normal controls recruited between January 2008 and January 2012. The AS patients were recruited from the spinal surgery department in one single center, and the healthy controls were enrolled at the center for physical examinations. All AS patients met the following inclusion criteria: (1) the diagnosis of AS fulfilled the modified New York criteria; 24 (2) having standing anteriorposterior and lateral radiographs of the entire spine; (3) having completed visual analog scale (VAS), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 11 Bath Ankylosing Spondylitis Radiology Index for sacroiliac joints (BASRI-SJ), 5 and the Bath Ankylosing Spondylitis Functional Index (BASFI) 5 for evaluating disease activity, severity, and functional status; and (4) availability of ESR, CRP, and HLA-B27. Lateral radiographs of the entire spine were scored using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). According to this method, the anterior vertebral corners (VCs) of the cervical and lumbar segments (total of 24 VCs) are scored on a lateral view only for the presence of an erosion and/or sclerosis and/or squaring (one point), syndesmophyte (two points), and bridging syndesmophyte (three points). 25 The total score ranges from 0 to 72. On the basis of the ASAS diagnostic criteria, 26 21 patients with early-stage AS were identified in this study. The demographic and clinical characteristics of all AS patients and controls are summarized in Table 1 . Five milliliters of venous blood was collected from all AS patients and healthy controls. To harvest cellfree serum, each coagulated blood sample was immediately centrifuged at 3000 rpm for 15 minutes, and the supernatant serum was recovered and then stored at À808C for further analysis. The study was approved by the ethical committee in our hospital. Written informed consent was obtained before the patients and healthy volunteers were entered into this study according to the Declaration of Helsinki.
A multiphase, case-control study was designed to identify serum miRNAs as surrogate markers for AS (Figure 1 ). In the initial biomarker screening stage, Solexa sequencing was employed to identify significantly altered miRNAs using pooled serum samples from 10 AS patients and 10 controls. Subsequently, a biomarker confirmation analysis with a hydrolysis probe-based qRT-PCR assay was performed to 
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Serum miR-146a and miR-155 as Novel Noninvasive Complementary Biomarkers Qian et al refine the number of serum miRNAs in AS signature. The analysis was separated into two phases: (1) in the training set (biomarker-selection phase), miRNAs were measured in the serum samples from 10 AS patients and 10 healthy controls; and (2) in the validation set (biomarker-validation phase), miRNAs were measured in serum samples from an additional 70 AS patients and 68 healthy controls. AS patients in the training and validation sets were further divided into two groups based on the severity of thoracolumbar kyphosis, that is, the magnitude of global kyphosis (GK), 27 (mild deformity: GK <708; severe deformity: GK !708). 28 It was measured using the Cobb method, defined as the angle between the superior endplate of the maximally tilted upper end vertebra and the inferior endplate of the maximally tilted lower end vertebra on the lateral radiograph of the entire spine. 27 Of them, 32 AS patients with GK <708 were in group A and 38 AS patients with GK !708 were in group B.
Serum RNA Extraction
RNA was isolated from serum samples using a mirVana PARIS kit (Ambion, Austin, TX) according to the manufacturers' protocol. Subsequently, RNA was eluted in 50 uL of nuclease-free water, and stored at À808C for further analysis. The RNA concentration was measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE).
Solexa Sequencing
The total RNA of 10 AS patients and 10 healthy controls was purified directly for Solexa sequencing analysis using an Illumina Genome Analyzer (Illumina) according to the manufacturer's instructions. The total RNA concentration of samples for Solexa sequencing was at least more than 5 ng/uL containing less protein and salt ion impurities. After PAGE purification of small RNA molecules under 30 bp and ligation of a pair of Solexa adaptors to the RNA 5' and 3' ends, RNA molecules were reversely transcribed and amplified using primers to the adaptor regions for 17 cycles. Fragments around 90 bp (small RNA and adaptors) of PCR products were isolated from agarose gels. Purified DNA was used for cluster generation and sequencing analysis using an Illumina Solexa Sequencer (Illumina). After a bioinformatics analysis, the remaining miRNAs were searched against the Sanger miRBase (version15.0) to identify conserved, known miRNAs and novel miRNA. Then, significance analysis of microarray (SAM) (version 4.0) was performed to select miRNAs (Stanford University, Stanford, CA). Hierarchical cluster analysis was conducted using Gene Cluster 3.0 software (Stanford University).
Reverse Transcription (RT) and Quantitative Real-Time PCR (qPCR)
To determine miRNA levels in serum samples, RT and qPCR kits (Applied Biosystems, Foster City, CA) were used. RT reactions were performed using the TaqMan microRNA Reverse Transcription Kit (Applied Biosystems) in a final volume of 15 uL (168C for 30 min, 428C for 30 min, 858C for 5 min, and hold at 48C).
For real-time PCR, the reaction mix contains 10 uL TaqMan Universal PCR Master Mix with no AmpErase UNG, 0.5 uL miRNA TaqMan primers, 4 uL diluted RT product, and 5.5 uL nuclease-free water. All reactions were preformed in triplicate on a 7500 Real-time system (Applied Biosystems) with the following conditions: 958C for 10 min, followed by 40 cycles at 958C for 15 s, and 608C for 1 min. For qRT-PCR data, the expression level of miRNA was normalized to miR-16. 15 The threshold cycle (C T ) is defined as the fractional cycle number at which the fluorescence exceeds the given threshold. The C T values from real-time PCR assays greater than 40 were treated as 40. The relative expression levels of each target miRNA were determined by the equation 2 ÀDC T , in which DC T was calculated as follows:
Statistical Analysis
All statistical analyses were performed using SPSS 17.0 software (SPSS Inc, Chicago, IL), and graphs were generated using GraphPad Prism 5 Software (Graph Pad Software, Inc, La Jolla, CA). The difference in the fold change of serum miRNAs between AS patients and controls was assessed by independent-samples t test, whereas the difference in serum miRNA concentration between these two groups was analyzed using Mann-Whitney test. The Pearson correlation coefficient was performed to evaluate the associations between BASFI, BASDAI, mSASSS, ESR, CRP, VAS, BASRI-SJ, and miRNAs. ROC curves were used to assess the diagnostic values of identified miRNAs. Significance was defined as P <0.05.
RESULTS
TaqMan microRNA Array of Serum miRNAs in AS Patients and Controls
The miRNAs in pooled serum samples from 10 AS patients or 10 healthy individuals were examined by Solexa sequencing. Of 536 serum miRNAs detected by Solexa sequencing, 71 miRNAs were differentially expressed in AS patients when compared with healthy subjects, including 38 upregulated and 33 downregulated miRNAs. These differentially expressed serum miRNAs were chosen for further study only when they met the following criteria: 16 (1) having at least 20 copies of miRNA expression; (2) mean fold change >2 or <0.5; and (3) P values <0.05. On the basis of these criteria, 19 serum miRNAs, of which 16 miRNAs were upregulated and 3 miRNAs were downregulated in AS patients compared with controls, were chosen for further analysis ( Figure 2 , Table 2 ).
Validation of Differentially Expressed miRNAs Expression by qRT-PCR
qRT-PCR assay was used to confirm the expression of candidate miRNAs. In the training set, miRNAs were measured in a separate set of individual serum samples from 10 AS patients and 10 healthy controls of the previous step. Only miRNAs with a mean fold change >2 or <0.5 and a P value <0.01 were selected for further analysis. Using the above-mentioned criteria, miR-146a and miR-155 were observed to be significantly upregulated in AS patients compared with controls.
In the validation set, the concentration of these two selected miRNAs was measured by qRT-PCR in a larger cohort comprising of 70 AS patients and 68 matched controls. The altered miRNAs patterns in the validation set were consistent with those in the training set. Compared with the controls, the levels of miR-146a and miR-155 were significantly higher in AS patients. The differential levels of these two miRNAs between 80 AS patients and the 78 controls were demonstrated in Figure 3A and B. In addition, the expression level of miR-155 in group B was significantly higher than that in group A ( Figure 3C ), whereas the results of miR-146a expression level showed no deference between group A and group B ( Figure 3D ).
Correlation Analysis and ROC Curve Analysis
The serum level of miR-155 was significantly correlated with BASDAI ( Figure 4A ) but not with BASFI. In contrast, there were no significant associations between miR-146a and BASDAI ( Figure 5A ) or BASFI. In patients with early stage AS, miR-155 expression level was significantly correlated with CRP ( Figure 4B ) and mSASSS ( Figure 4C) but not with ESR, VAS, and BASRI-SJ. However, no significant correlations between miR-146a and ESR, CRP ( Figure 5B ), VAS, mSASSS ( Figure 5C ), or BASRI-SJ were noted. To further test the diagnostic values of miR-146a and miR-155 for AS, ROC analysis was constructed using 80 AS patients and 78 healthy controls (including subjects in both training and validation sets). As shown in Figure 6 , the ROC analyses yielded the AUC values of 0.917 for miR-146a and 0.964 for miR-155. These results demonstrated that these two miRNAs were potentially useful biomarkers to differentiate AS patients from healthy controls. 
DISCUSSION
AS is a chronic inflammatory rheumatic disease that mainly affects the axial skeleton. 1 The inflammatory process culminates in ossification of the involved ligaments, leading to structural and functional impairments and a decrease in quality of life. 2 A prompt and accurate diagnosis of AS is essential for the early initiation of effective therapy, thereby greatly improving its prognosis. 6, 7 However, there is an unacceptably long delay between the onset of symptoms and the time of diagnosis for AS, with an average interval of 8 years. 11, 12 The current diagnostic approaches, including physical examinations, lab tests for HLA-B27, ESR and CRP, and imaging methods for detecting sacroiliac joints abnormalities (plain radiography, computed tomography (CT), or magnetic resonance imaging (MRI)) had limited value for early detection of AS. [8] [9] [10] Therefore, more sensitive and efficient biomarkers for AS detection are importantly needed.
To date, there has been only one study analyzing aberrant expression of miRNAs in AS patients; however, this study focused on miRNAs profile in T cells, with sample sizes (five AS patients vs. five healthy controls). 30 To the best of our knowledge, no data have been previously published for describing the global miRNA pattern in the sera of AS patients. Therefore, this is the first study specifically investigating the serum miRNA expression profile in AS patients to evaluate the potential utility of serum miRNAs as biomarkers for the diagnosis of AS. In the current study, two serum miRNAs (miR-146a and miR-155) were significantly upregulated in the serum of AS patients when compared with controls. Furthermore, ROC analysis indicated that miR-146a and miR-155 could differentiate AS patients from healthy controls with reasonable AUCs (0.917 and 0.964, respectively), suggesting that both these two miRNAs may serve as novel complementary biomarkers for the diagnosis of AS. However, it should be pointed out that like many other novel biomarkers at their early stages of research, extensive investigations of serum miRNAs are required to validate their great potential. Further studies are needed to explore the target genes of miR-146a and miR-155 in autoimmune inflammatory response in AS, which may help to understand the pathogenic mechanisms of AS, identify diagnostic biomarkers for AS, as well as design new therapeutic strategy to improve the effectiveness of AS treatment.
More importantly, miR-155 expression level was found to be significantly correlated with BASDAI and CRP, indicating that serum miRNA may have an application in the precise clinical description of AS. Although BASDAI and CRP are presently the most important parameters used to assess the disease activity, 11, 26 it is intriguing to speculate that serum miR-155 and miR-146a might have an important prognostic value and could serve as an important predictive parameter in the decision on adjuvant treatment protocols. In addition, a correlation between the level of miR-155 and mSASSS was found in patients with earlystage AS, suggesting that miR-155 may be a novel potential biomarker for predicting new bone formation in AS. However, a long-term longitudinal study is needed to validate its reliability. Of note, the serum level of miR-155 was observed to be significantly higher in AS patients with kyphosis !708 compared with those with kyphosis <708. Higher miR-155 expression level may indicate increased risk of severe thoracolumbar kyphosis in AS patients. The results could be explained by the aberrant expression of immunoinflammatory factors in the presence of higher expression level of miR-155. Higher expression of miR-155 can lead to an increase in the production of proinflammatory cytokines, including IL-6 and IL-23, which are inducers for the development of the autoreactive Th17 cells, and TNF-a, an established mediator of chronic inflammation. 31 Both IL-6 and TNF-a have been considered pivotal cytokines in the pathogenesis of AS. [1] [2] [3] Therefore, the AS patients with higher miR-155 expression level may have more excessive autoimmune responses against vertebrae, intervertebral discs, and/or soft tissues surrounding the spine, which finally results in the progression of thoracolumbar kyphosis.
Interestingly, the current study also showed an increased level of miR-146a in the sera of AS patients. In contrast, a decreased level of miR-146a in SLE patients compared with controls was reported in the study by Tang et al. 32 Given the fact that AS and SLE are both systemic rheumatic diseases, one may be confused by the finding that miR-146a expression profiles are inconsistent in these two disorders. However, this may simply reflect a difference in the overall cytokine profiles between the two clinical entities, with type I IFN playing a dominant role in SLE, 21 whereas TNF-a, IL-1, and IL-6 are the principle cytokines in AS. [1] [2] [3] One limitation of this study should be addressed. The expression levels of these miRNAs were investigated in most of patients with active AS (BASDAI; mean score, 4.4 AE 1.9; range, 1.3-9.5). Whether the expression pattern of these miRNAs in patients with active AS is different from that in patients with quiescent AS is still unknown. Hence, it would be ideal to include a separate group of patients with quiescent AS for comparison. Nevertheless, the distinctive serum miRNAs signature in AS was first identified by the current study.
In summary, the results of this study demonstrated that the expression profile of the two serum miRNAs (miR-146a and miR-155) may serve as noninvasive complementary biomarkers for the diagnosis of AS, which also provide an impetus for future evaluations of the clinical value of serum miRNAs to predict therapeutic efficacy. In addition, the expression level of miR-155 was associated with the disease activity, severity, and structural damage. 
